Disclosure-driven uncertainty in China’s antibody drug patent examination: enablement, support and a roadmap for foreign applicants

This article examines disclosure-driven uncertainty in China’s examination of antibody drug patents and asks how foreign applicants can secure protection under the China National IP Administration’s practice. China has become a key jurisdiction for antibody drug innovation and first approvals. Yet, its patent disclosure regime remains largely calibrated to chemical drugs, giving rise to unpredictability in the enablement and claim-support review. We combine doctrinal analysis of the Chinese Patent Law and the Chinese Guidelines for Patent Examination with practice-based review of prosecution dynamics to identify key frictions and develop a clear prosecution roadmap. We find that (i) enablement standards lack stable operational guidance, (ii) claim-support review is comparatively stringent, especially for functionally based claiming and (iii) disclosure defects are sometimes folded into inventive-step analysis. Practically, applicants should front-load robust experimental evidence, build a tiered claim architecture, respond to office actions with a diagnosis and rebuttal structure, avoid cross-references by strengthening written documentation, and use incorporation by reference mechanisms to cure filing-stage omissions where eligible.